IFIH1 and dermatomyositis: We previously conducted a longitudinal analysis of anti-MDA5 antibody levels in DM patients using the previous version of the ELISA [28, 29], and found that high levels of anti-MDA5 antibodies at diagnosis were useful for predicting poor outcomes.